Edition:
United States

Auris Medical Holding AG (EARS.OQ)

EARS.OQ on NASDAQ Stock Exchange Capital Market

1.38USD
23 Apr 2018
Change (% chg)

$-0.06 (-4.17%)
Prev Close
$1.44
Open
$1.43
Day's High
$1.43
Day's Low
$1.37
Volume
3,649
Avg. Vol
35,888
52-wk High
$9.70
52-wk Low
$1.24

Chart for

About

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United... (more)
No analyst recommendations are available for .

Overall

Beta: 0.76
Market Cap(Mil.): $8.81
Shares Outstanding(Mil.): 6.12
Dividend: --
Yield (%): --

Financials

  EARS.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -5.85 -- --
ROI: -143.16 -0.74 13.19
ROE: -407.48 -2.80 15.00

BRIEF-Auris Medical Announces Early Repayment Of Part Of Its Loan Facility

* AURIS MEDICAL ANNOUNCES EARLY REPAYMENT OF PART OF ITS LOAN FACILITY

Apr 09 2018

BRIEF-Thomas Meyer Reports 12.6 Pct Stake In Auris Medical As Of March 29

* THOMAS MEYER REPORTS 12.6 PCT STAKE IN AURIS MEDICAL HOLDING AG AS OF MARCH 29, 2018 - SEC FILING‍​ Source text: (https://bit.ly/2uJaqwA) Further company coverage:

Apr 03 2018

BRIEF-Auris Regains Compliance With Nasdaq's Minimum Bid Price Requirement

* AURIS REGAINS COMPLIANCE WITH NASDAQ'S MINIMUM BID PRICE REQUIREMENT Source text for Eikon: Further company coverage:

Mar 29 2018

BRIEF-Auris Medical Q4 Loss Per Share CHF 0.10

* AURIS MEDICAL PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 22 2018

BRIEF-Auris Medical Holding AG - Shareholders Approved Merger Between Co And Auris Medical Newco - SEC Filing

* AURIS MEDICAL HOLDING AG - ON MARCH 12, AT THE GENERAL MEETING, SHAREHOLDERS APPROVED MERGER BETWEEN CO AND AURIS MEDICAL NEWCO - SEC FILING

Mar 13 2018

BRIEF-Auris Medical Provides Business Update

* AURIS MEDICAL HOLDING AG - PRELIMINARY TOP-LINE DATA FROM TACTT3 TRIAL INDICATE THAT STUDY DID NOT MEET ITS PRIMARY EFFICACY ENDPOINT

Mar 13 2018

BRIEF-Auris Medical Holding AG Files For Resale Of Up To 7.5 Mln Common Shares Issuable Upon Exercise Of Certain Outstanding Warrants

* AURIS MEDICAL HOLDING AG FILES FOR RESALE OF UP TO 7.5 MILLION COMMON SHARES ISSUABLE UPON EXERCISE OF CERTAIN OUTSTANDING WARRANTS - SEC FILING Source text: [http://bit.ly/2BPfTod] Further company coverage:

Feb 09 2018

BRIEF-Auris Medical Reports New Data Highlighting Superior Bioavailability Of AM-125

* AURIS MEDICAL REPORTS NEW DATA HIGHLIGHTING SUPERIOR BIOAVAILABILITY OF AM-125 COMPARED TO ORAL BETAHISTINE

Feb 07 2018

BRIEF-Auris Medical Announces Pricing Of $5.5 Mln Registered Direct Offering

* AURIS MEDICAL ANNOUNCES PRICING OF $5.5 MILLION REGISTERED DIRECT OFFERING

Jan 29 2018

BRIEF-Auris Medical Announces Further Results From Healos Phase 3 Trial

* AURIS MEDICAL HOLDING AG SAYS ANNOUNCED FURTHER CLINICAL RESULTS FROM THE HEALOS PHASE 3 CLINICAL TRIAL, PROVIDES UPDATE ON AM-111 DEVELOPMENT PROGRAM

Jan 04 2018

Earnings vs. Estimates